Why Consider a Specialized CRO
In vivo research hinges on decisions that can shape reproducibility, interpretation, and confidence in the final dataset. While many CROs offer broad capabilities across major therapeutic areas, the best fit may come down to model-specific expertise, technical nuance, and experience with the exact protocol and endpoints. This blog covers why seemingly minor experimental details can have an outsized impact on in vivo studies, the value of model-specific CRO expertise, and how a study-first approach can help researchers identify the right partner for the work.
Not Every Capable CRO Is the Right CRO
Once study design is complete, the next step for many preclinical researchers is to identify a CRO capable of executing the plan. There is no shortage of high-quality CROs, but a wide range of available options does not necessarily mean that every provider is a suitable fit for a particular study. Broad therapeutic areas such as oncology or neurology can help narrow the field, but they are not sufficient criteria for selecting a specific CRO. Two studies within the same disease area can require very different species or strains, dosing routes, endpoints, imaging infrastructure, tissue-processing workflows, or welfare considerations. Moreover, while technical capability is essential, deep, accumulated experience can be just as valuable when unexpected complications arise, as they often do in preclinical research.
Why the Minor Details Matter
Scientists know that details matter in study design, yet CRO selection can sometimes focus on broad requirements while overlooking smaller factors that may significantly affect study outcomes. For example, studies in mice and rats have shown that the sex of the experimenter can influence pain responses, with potential implications for behavioral assays1. Another source of variation is rodent gut microbiota, whose composition can be influenced by diet, housing and husbandry conditions, and animal source or supplier2. Another example comes from tumor xenograft studies, a common feature of preclinical oncology research. Researchers may not always think to ask what passage number a CRO will use, yet passage history can influence cell phenotype, tumor growth kinetics, and treatment response, making it a seemingly minor variable with potentially significant experimental consequences3,4. In this context, having the right cell line “available” is a starting point, not a guarantee of genuine, expert-driven capability.
The Value of a Specialized CRO
The above examples may seem highly specific, but they illustrate that rigorous study design and execution depend on far more than high-level decisions about therapeutic area and model. Scientists will recognize the difference between following a standard vendor protocol and working with the added context, practical guidance, and technical insight that come from years of hands-on experience. A first-year PhD student, for example, is more likely to succeed with guidance from an experienced postdoc than by relying solely on the methods section of a polished manuscript. The same principle applies to CRO selection.
None of this is an argument against large, broad-service CROs. They remain essential to drug development, particularly where scale, capacity, integrated services, standardized processes, and multidisciplinary coordination are required. Smaller specialist CROs can offer a different kind of value, especially for focused studies that rely on niche technical expertise, proprietary or vendor-specific models, or substantial experience with a particular assay or endpoint.
Adopting a Study-First Mindset
A useful way to approach CRO selection is to treat it as an extension of study design rather than a separate process. This approach puts the study’s specific requirements at the center of vendor selection from the outset, allowing CROs to be qualified at the appropriate level of detail early on, reducing time spent engaging with providers that meet broad therapeutic-area criteria but lack the more specific capabilities the study requires.
Broad and deep evaluation of suitable vendors is essential, while avoiding the temptation to adapt the study to fit a particular CRO. Speaking directly with the scientists who will perform the work can help teams assess their expertise, understanding of the model, and familiarity with factors that may affect study quality.
Matching CROs to Studies in a Fraction of the Time: ModernVivo Marketplace
Matching highly detailed study requirements with the right CRO capabilities can be a time-consuming process that ultimately slows development. The ModernVivo Marketplace addresses this challenge by pre-vetting CROs against the specific requirements of each study, including the finer details that can influence execution and outcomes. This can significantly reduce the time teams spend identifying the right partner, helping them move into development faster and with greater confidence.
ModernVivo Marketplace is free for all preclinical research teams. Find your ideal CRO today.
References
1. Sorge RE, Martin LJ, Isbester KA, et al. Olfactory exposure to males, including men, causes stress and related analgesia in rodents. Nat Methods. 2014;11(6):629-632. doi:10.1038/nmeth.2935
2. Franklin CL, Ericsson AC. Microbiota and reproducibility of rodent models. Lab Anim. 2017;46(4):114-122. doi:10.1038/laban.1222
3. Stribbling SM, Beach C, Ryan AJ. Orthotopic and metastatic tumour models in preclinical cancer research. Pharmacol Ther. 2024;257:108631. doi:10.1016/j.pharmthera.2024.108631
4. Prasad CP, Tripathi SC, Kumar M, Mohapatra P. Passage number of cancer cell lines: Importance, intricacies, and way-forward. Biotechnol Bioeng. 2023;120(8):2049-2055. doi:10.1002/bit.28496